A Chinese study has observed that the dye indocyanine green may lessen the toxic effects of consuming the amanita phalloides mushroom.
- Amanita phalloides poisoning leads to phalloid syndrome, responsible for digestive, renal and hepatic symptoms.
- Currently, there is no treatment to reverse the toxic effects associated with the consumption of the amanita phalloides mushroom.
- A dye, used for medical imaging examinations, could be a therapeutic lead against human poisoning by fungi.
Also called “chalice of death”, the amanita phalloides is a particularly toxic mushroom, which can be very easily confused with an edible mushroom. This vegetable produces toxins, which are not destroyed during cooking, in particular alpha-amanitine. They are responsible for the phalloid syndrome, which is accompanied by digestive, renal and hepatic disorders, and which can lead to the death of the patient in 10 to 15% of cases, indicates ANSES.
Amanita phalloides poisoning: a new therapeutic avenue discovered
For now, there is no antidote to reverse the effects of amanita phalloides poisoning. A potential avenue of treatment is however considered in a new study published in the scientific journal NatureCommunications.
As part of this research, scientists from Sun Yat-Sen University in Ghangzhou (China) targeted the toxin alpha-amanitin with a CRISPR genetic screen to determine the role of genes in poisonings. Using this tool, the researchers identified the protein STT3B, which causes amanita phalloides toxicity.
Indocyanine green may reduce the toxic effects of amanita phalloides
In a second step, those responsible for the study examined the database of the Food and Drug Administration (FDA), in order to detect a potential antidote. They then discovered a molecule that could fight against its effects: indocyanine green (ICG), a dye used in medical imaging diagnostics.
They then tested the product on liver cells and a mouse. Indocyanine green”demonstrated significant potential in mitigating the toxic effect of mushroom poisoning”said Quiaoping Wang, lead author of the study and a researcher at Sun Yat-sen University, to AFP. Now, the Chinese team wants to confirm its results by carrying out clinical trials in humans.
Leave a Reply